 Insulin glulisine

Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.It was developed by Sanofi-Aventis and is sold under the trade name Apidra.